Protagenic Therapeutics, Inc. (PTIX) Ownership
PTIX ownership summary
as of October 21, 2026- Institutions
- 3.7% of shares outstanding
- Insiders
- 6.20% of shares outstanding
- Shares outstanding
- 1.8M
- Float
- 1.7M shares available to trade
- Short interest
- 2.72% 62K shares short
- Days to cover
- 0.52 short interest up 15.5% vs prior month
- Institutions 3.69%
- Insiders 6.20%
- Other investors 90.11%
PTIX top institutional holders
10 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | DRW Securities, LLC | 2.31% | 42K | $30,084 | −1,071 (−2.5%) | March 31, 2026 |
| 2 | United Financial Planning Group LLC | <0.01% | 17 | $12 | — | March 31, 2026 |
| 3 | Morgan Stanley - Brokerage Accounts | 0.00% | — | — | −2 (−100.0%) | March 31, 2026 |
| 4 | Geode Capital Management, LLC | 0.00% | — | — | −12,182 (−100.0%) | March 31, 2026 |
| 5 | Tower Research Capital LLC | 0.00% | — | — | −3,045 (−100.0%) | March 31, 2026 |
| 6 | HARBOR INVESTMENT ADVISORY, LLC | 0.00% | — | — | −1 (−100.0%) | March 31, 2026 |
| 7 | Advisor Group Holdings, Inc. | 0.00% | — | — | −49 (−100.0%) | March 31, 2026 |
| 8 | CoreCap Advisors, LLC | 0.00% | — | — | −100 (−100.0%) | June 30, 2026 |
| 9 | Bank of America Corp | 0.00% | — | — | −17 (−100.0%) | March 31, 2026 |
| 10 | Citadel Advisors Llc | 0.00% | — | — | −23,311 (−100.0%) | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 10, 0 holders added 0 shares and 9 cut 40K.
PTIX top mutual fund and ETF holders
1 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | SSgA U.S. Total Market Index Strategy | <0.01% | 36 | $26 | — | September 30, 2025 |
Funds report holdings monthly or quarterly; dates differ by fund.
PTIX insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2023-10-12 | Alexander K Arrow | Buy | $11.34 | 571 | $6,475 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
PTIX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns PTIX
Institutional investors own 3.7% of Protagenic Therapeutics's shares and insiders 6.20%. The largest holder is DRW Securities, LLC with 2.31% of the shares (42K), as of March 31, 2026. Among the top 10 institutions, 0 added shares and 9 reduced their stake in the latest filings. Short interest is 2.72% of the float, or 0.52 days of average trading volume. The share count rose 29,667.7% since 2014.
Related: PTIX analyst forecast, PTIX key metrics. See the PTIX stock overview for the latest quote and news.
PTIX ownership FAQ
Who owns the most Protagenic Therapeutics stock?
The largest shareholders of Protagenic Therapeutics are DRW Securities, LLC (2.31%), United Financial Planning Group LLC (<0.01%), Morgan Stanley - Brokerage Accounts (0.00%), Geode Capital Management, LLC (0.00%), Tower Research Capital LLC (0.00%).
What percentage of Protagenic Therapeutics is owned by institutions?
Institutions hold 3.7% of Protagenic Therapeutics's shares outstanding; insiders hold 6.20%.
Which funds own Protagenic Therapeutics?
The largest fund holders of Protagenic Therapeutics are SSgA U.S. Total Market Index Strategy (<0.01%).
What is Protagenic Therapeutics's short interest?
62K shares of Protagenic Therapeutics were sold short, 2.72% of the float; at the average daily volume it would take 0.52 days to cover.
Are insiders buying or selling Protagenic Therapeutics?
Of the latest 1 reported insider transactions in Protagenic Therapeutics (since October 12, 2023), 1 were purchases and 0 were sales.
How many shares of Protagenic Therapeutics are outstanding?
Protagenic Therapeutics has 1.8M shares outstanding, of which 1.7M are in the public float.